Skip to main content

Food and Drug Law Institute Annual Conference

Regenerative Medicine, Gene Therapies, and FDA Regulation


Date: May 3, 2019

Time: 9:45AM - 10:30AM

Location: Washington, DC

Joanne Hawana will be moderating a panel entitled "Regenerative Medicine, Gene Therapies, and FDA Regulation" at the Food and Drug Law Institute Annual Conference in Washington, DC.

Panel Description:

The tools provided to FDA under the 21st Century Cures Act have been used by CBER to promote the development of new gene, cell, and tissue therapies. We have seen trends emerging in the regenerative medicine/stem cell fields, including science-based development of cell therapies via the RMAT designation in the Cures Act, and efforts FDA is taking to regulate rogue stem cell clinics.

Marc J. Scheineson, Partner, Alston & Bird LLP
Michael Werner, Partner, Holland & Knight LLP
Celia M. Witten, Deputy Director, CBER, FDA
Moderated by Joanne Hawana, Member, Mintz


Professional Cropped Hawana Joanne Mintz

Joanne S. Hawana


Joanne S. Hawana counsels global Mintz clients on regulatory and distribution-related considerations for new FDA-regulated products. She also advises clients on the business impacts of new federal and state actions on food, drugs, cosmetics, electronic nicotine systems, and medical devices.